RE:RE:Glioblastoma market US$4.2 billion in 2028"It will be years before xB3 versions of Midatech's drugs can be designed, put through preclinical studies and then clinical trials. Over five years. That's a minimum."
Given the potential market:
"That's a C$5.67 billion market in 2028 in Canadian dollars."
Could Biodexa be seen as having a compelling and leading potential solution in the next 1-2 years. With even a 10% probability of a leading poisition that could mean a huge payout early on.